| A361 |
Sofituzumab Biosimilar(Anti-MUC16 Reference Antibody)
Featured
|
Sofituzumab (MMUC 1206A) is a humanizedized anti-MUC16 recombinant V-kappa antibody. |
|
| A362 |
Forerunner patent anti-Muc 17 Biosimilar(Anti-MUC17 Reference Antibody)
Featured
|
|
|
| A363 |
Argenx patent anti-MuSK Biosimilar(Anti-MUSK Reference Antibody)
Featured
|
|
|
| A364 |
Alt-100 Biosimilar(Anti-NAMPT Reference Antibody)
Featured
|
|
|
| A365 |
Lifastuzumab Biosimilar(Anti-NaPi2b / SLC34A2 Reference Antibody)
Featured
|
Lifastuzumab is a humanized anti-NaPi2b monoclonal antibody (IgG1 type). Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) through ADC Linker to form an antibody-drug conjugate (ADC) lifastuzumab vedotin (DNIB0600A) with anticancer activity. |
|
| A366 |
Upifitamab Biosimilar(Anti-NaPi2b / SLC34A2 Reference Antibody)
Featured
|
Upifitamab is an ADC Antibody (a naked antibody of upifitamab rilsodotin), which can be used for antibody-coupled agent (ADC) synthesis. Upifitamab rilsodotin is an ADC targeting NaPi2b and is used in ovarian cancer research, particularly in platinum-resistant recurrent ovarian cancer. |
|
| A367 |
Lorvotuzumab Biosimilar(Anti-NCAM1 / CD56 Reference Antibody)
Featured
|
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine. |
|
| A368 |
Enfortumab Biosimilar(Anti-Nectin-4 Reference Antibody)
Featured
|
Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma. |
|
| A369 |
Tanezumab Biosimilar(Anti-NGF / bNGF Reference Antibody)
Featured
|
Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia. |
|
| A370 |
Fasinumab Biosimilar(Anti-NGF / bNGF Reference Antibody)
Featured
|
Fasinumab (Anti-Human NGF) is a human IgG4 monoclonal antibody to nerve growth factor (NGF). Fasinumab can be used in acute sciatica and knee osteoarthritis (OA) studies. |
|
| A371 |
MEDI-578 Biosimilar(Anti-NGF / bNGF Reference Antibody)
Featured
|
|
|
| A372 |
Fulranumab Biosimilar（Anti-NGF / bNGF Reference Antibody）
Featured
|
Fulranumab is a human IgG2 monoclonal antibody against nerve growth factor (NGF) and can be used for the research of pain. |
|
| A373 |
AS2886401-00 Biosimilar（Anti-NGF / bNGF Reference Antibody ）
Featured
|
|
|
| A374 |
Monalizumab Biosimilar（Anti-NKG2A / CD94 Reference Antibody）
Featured
|
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC). |
|
| A375 |
Tesnatilimab Biosimilar（Anti-NKG2D / CD314 Reference Antibody）
Featured
|
Tesnatilimab is a human IgG4 monoclonal antibody that acts on the immune activating receptor NKG2D and has potential immunomodulatory and anti-inflammatory activity. Tesnatilimab can be used in the study of inflammatory bowel disease (IBD). |
|
| A376 |
Abbott patent anti-NGR Biosimilar（Anti-Nogo Receptor / NgR Reference Antibody）
Featured
|
|
|
| A377 |
Pfizer patent anti-Notch1 Biosimilar（Anti-NOTCH1 Reference Antibody）
Featured
|
|
|
| A378 |
Tarextumab Biosimilar（Anti-NOTCH3 Reference Antibody）
Featured
|
Tarextumab (OMP-59R5) is an anti-Notch2/3 fully human IgG2 monoclonal antibody. Tarextumab shows anti-tumor activity. |
|
| DC67002 |
Genentech patent anti-Notch
Featured
|
|
|
| A380 |
Vesencumab Biosimilar（Anti-NRP1 / VEGF165R / CD304 Reference Antibody）
Featured
|
Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer. |
|
| A381 |
Uliledlimab Biosimilar（Anti-NT5E / CD73 Reference Antibody）
Featured
|
Uliledlimab is a potent against CD73 humanizedized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer. |
|
| A382 |
Oleclumab Biosimilar(Anti-NT5E / CD73 Reference Antibody)
Featured
|
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity. |
|
| A383 |
Mupadolimab Biosimilar(Anti-NT5E / CD73 Reference Antibody)
Featured
|
Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73POS B cells. |
|
| A384 |
Amgen patent anti-ORAI1 Biosimilar(Anti-Orai1 Reference Antibody)
Featured
|
|
|
| A385 |
Vixarelimab Biosimilar(Anti-OSMR Reference Antibody)
Featured
|
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash. |
|
| A386 |
ASK8007 Biosimilar(Anti-Osteopontin Reference Antibody)
Featured
|
|
|
| A387 |
Janssen patent anti-CD200R1 Biosimilar（Anti-OX2R / CD200R1 Reference Antibody）
Featured
|
|
|
| A388 |
Orticumab Biosimilar（Anti-oxLDL Reference Antibody）
Featured
|
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement. |
|
| A389 |
Okayama U. patent anti-oxLDL Biosimilar(Anti-oxLDL Reference Antibody)
Featured
|
|
|
| A390 |
Zelminemab Biosimilar(Anti-PAC1 Reference Antibody)
Featured
|
Zelminemab (AMG-301) is a humanized monoclonal antibody that inhibits PACAP type I (PAC1) receptor. |
|
